GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (HKSE:02186) » Definitions » Retained Earnings

Luye Pharma Group (HKSE:02186) Retained Earnings : HK$0 Mil (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Luye Pharma Group's retained earnings for the quarter that ended in Dec. 2024 was HK$0 Mil.

Luye Pharma Group's quarterly retained earnings increased from Dec. 2023 (HK$0 Mil) to Jun. 2024 (HK$6,940 Mil) but then declined from Jun. 2024 (HK$6,940 Mil) to Dec. 2024 (HK$0 Mil).


Luye Pharma Group Retained Earnings Historical Data

The historical data trend for Luye Pharma Group's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group Retained Earnings Chart

Luye Pharma Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Luye Pharma Group Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 6,940.31 -

Luye Pharma Group Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Luye Pharma Group  (HKSE:02186) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Luye Pharma Group Business Description

Traded in Other Exchanges
Address
Hongqiao Road 1438, 22/F, Gubei International Fortune Center II, Changning District, Shanghai, CHN, 264003
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, Cardiovascular system drugs, Alimentary tract and metabolism drugs and Central nervous system drugs. It derives maximum revenue from the sale of Oncology drugs.
Executives
Ubs Group Ag 2201 Interest of corporation controlled by you
Liu Dianbo 2301 Trustee
Luye Life Sciences Group Ltd 2201 Interest of corporation controlled by you
Luye Pharma Holdings Ltd. 2201 Interest of corporation controlled by you
Luye Pharmaceutical International Co., Ltd.
Luye Pharmaceutical Investment Co., Ltd.
Nelumbo Investments Limited 2201 Interest of corporation controlled by you
Shorea Lbg 2201 Interest of corporation controlled by you
Ginkgo (ptc) Limited 2301 Trustee
Luye Pharmaceutical International Co., Ltd. 2201 Interest of corporation controlled by you
Luye Pharmaceutical Investment Co., Ltd. 2101 Beneficial owner
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Hillhouse Nev Holdings Limited 2101 Beneficial owner
Hillhouse Investment Management, Ltd. 2102 Investment manager
Hillhouse Fund V, L.p. 2201 Interest of corporation controlled by you

Luye Pharma Group Headlines

No Headlines